Comparison of Complement Fixation and Hemagglutination Inhibition Assays for Detecting Antibody Responses following Influenza Virus Vaccination

Harry E. Prince* and Amy L. Leber

Focus Technologies, Cypress, California, and Quest Diagnostics, San Juan Capistrano, California

Received 23 December 2002/Returned for modification 13 February 2003/Accepted 4 March 2003

Complement fixation (CF) was compared to hemagglutination inhibition (HI) as a method for identifying antibody responses to influenza virus vaccination. CF assays were performed at two different laboratories using paired (pre- and postvaccination) sera from 38 vaccinated laboratory employees; HI assays were performed at a third laboratory. As expected, most vaccinees (31/38 = 82%) responded to at least one of three influenza virus antigens as measured by HI. In contrast, only 21% (8/38) of vaccinees showed a response by CF at laboratory 1, and only 29% (11/38) showed a response by CF at laboratory 2. These findings indicate that due to low sensitivity, CF assays should not be used to assess the antibody response to influenza virus vaccination.

Several studies have clearly demonstrated that hemagglutination inhibition (HI) is a more sensitive method than complement fixation (CF) for detecting antibody responses to naturally occurring influenza virus A and influenza virus B infections (4, 6, 8). HI detects antibodies to strain-specific hemagglutinins, whereas CF mainly detects antibodies to type-specific nucleoproteins (9). Hemagglutinins are used as antigens in influenza virus vaccines, thus making HI the method of choice for measuring vaccine-induced antibodies (1, 2, 3, 5).

Because HI assays for influenza virus antibodies are not widely available, clinicians often ask whether CF is an acceptable method for assessing the influenza virus vaccine responses of their patients. Although the points mentioned above argue against the use of CF assays to monitor vaccine responses, a search of the National Library of Medicine database did not identify any reports directly comparing CF and HI for detecting influenza virus vaccine-induced antibodies. We thus conducted a study to verify that HI is more sensitive than CF for measuring antibody responses to influenza virus vaccination and to provide comparative data for dissemination to inquiring clinicians.

Subjects. Study participants included 38 Focus Technologies employees electing to receive influenza virus vaccination in December 2001 (vaccinees) and 11 employees electing not to receive the vaccine (controls). All study participants were between 19 and 63 years of age and provided informed consent for specimen collection. Vaccinees donated a prevaccination blood specimen and then received the 2001-to-2002 trivalent influenza virus vaccine (Aventis Pasteur, Swiftwater, Pa.) 1 to 12 days later (median, 7 days). The vaccine contained the hemagglutinins of influenza virus A/New Caledonia/20/99 (H1N1), influenza virus A/Panama/2007/99 (H3N2), and influenza virus B/Victoria/504/2000. Vaccinees then donated a second blood specimen 16 to 32 days (median, 21 days) following vaccination. Two blood specimens were also obtained from controls; the time between collection of the two samples ranged from 24 to 28 days (median, 26 days). None of the vaccinees or controls self-reported influenza virus infection in the 4 months following the donation of the blood samples. All blood specimens were processed within 8 h of collection, and the serum was stored in 1.0-ml aliquots at −70°C. All sera were coded such that individuals performing HI and CF assays were unaware of the donors' vaccination status.

HI. Using a starting dilution of 1:5, serum HI titers to the vaccine components were measured by Retroscreen Virology Ltd. (London, United Kingdom) as previously described (1). Coded sera were tested in run sizes of 8 to 20 samples following a plan designed by the authors; paired sera from a given study participant were tested on the same assay run. A positive response was defined as a fourfold increase in titer between pre- and postvaccination sera; a titer of <5 was assigned a titer value of 2.5.

CF. Using a starting dilution of 1:8, serum CF titers to influenza virus A and influenza virus B (hereafter referred to as A and B, respectively) (BioWhittaker, Walkersville, Md.) were measured following established procedures in two different laboratories (7). Coded sera were tested in run sizes of 8 to 20 samples as outlined by the authors; paired sera from a given study participant were tested on the same assay run. A positive response was defined as a fourfold increase in titer between pre- and postvaccination sera; a titer of <8 was assigned a titer value of 4.

As shown in Table 1, 31/38 (82%) vaccinees exhibited an antibody response to at least one influenza virus antigen as assessed by HI. Although 2/11 (18%) unvaccinated controls also showed a response to A by HI, the difference between the proportions (82 versus 18%) was statistically significant (defined [using contingency table analysis] as \( P < 0.01 \)). In contrast to the high rate of responses noted in the vaccinee group by HI, the response rates as assessed by CF were markedly lower. Only 8/38 (21%) vaccinees showed a response to A and/or B as assessed by CF testing performed at laboratory 1, and only 11/38 (29%) showed a response by CF testing performed at laboratory 2. Both of these proportions were statis-
TABLE 1. HI and CF response patterns following influenza virus vaccination

| Antibody response pattern by HI | No. of donor samples exhibiting the indicated CF response pattern at: |
|-------------------------------|-------------------------------------------------------------------|
|                               | Laboratory 1 | Laboratory 2 |
|                               | A nor B | A | B | A and B | A nor B | A | B | A and B |
| Neither                       | 7 | 0 | 0 | 0 | 6 | 0 | 0 | 1 |
| B                             | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| A                             | 13 | 9 | 1 | 2 | 1 | 9 | 2 | 2 | 0 |
| Both                          | 38 | 30 | 1 | 5 | 2 | 27 | 2 | 4 | 5 |

*Antibody response patterns were as follows: neither, negative for A-NC and/or A-Pan as well as for B; B, positive for B but negative for A-NC and/or A-Pan; A, positive for A-NC and/or A-Pan but negative for B; both, positive for A-NC and/or A-Pan as well as for B; A-NC, influenza virus A/New Caledonia; A-Pan, influenza virus A/Panama.

We thank Carolyn Ernst-Shoup, Nimfa Burgos, Dulia Castro, and Sandra Hazelton for expert technical assistance.

REFERENCES

1. Gelder, C. M., R. Lamkin, K. W. Hart, D. Fleming, O. M. Williams, M. Bunce, K. I. Welsh, S. E. Marshall, and J. Oxford. 2002. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J. Infect. Dis. 185:1117–1117.

2. Gorsky, J. J., J. W. Fulbright, C. S. Crowson, G. A. Poland, W. M. O’Fallon, and C. M. Weyand. 2001. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol. 75:12182–12187.

3. Gross, P. A., C. Russo, M. Teplitzky, S. Dran, P. Catarozolo, and G. Munk. 1996. Time to peak serum antibody response to influenza vaccine in the elderly. Clin. Diagn. Lab. Immunol. 3:616–616.

4. Julkunen, I., R. Pyhala, and T. Hovi. 1985. Enzyme immunosassay, complement fixation and hemagglutination inhibition tests in the diagnosis of influenza A and B virus infections. Purified hemagglutinin in subtype-specific diagnosis. J. Virol. Methods 18:75–84.

5. Kunzel, W., H. Glathe, H. Engelmann, and C. Van Hoecke. 1996. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 14:1108–1110.

6. Madore, H. P., R. C. Reichman, and R. Dolin. 1983. Serum antibody responses to naturally occurring influenza A virus infection determined by enzyme-linked immunosorbent assay, hemagglutination inhibition, and complement fixation. J. Clin. Microbiol. 18:1325–1330.

7. Palmer, D. F., and S. D. Whaley. 1986. Complement fixation test, p. 57–66. In N. R. Rose, H. Friedman, and J. L. Fahey (ed.), Manual of clinical laboratory immunology, 3rd ed. American Society for Microbiology, Washington, D.C.

8. Pyhala, R., and M. Kleemola. 1976. The value of complement fixation and hemagglutination inhibition tests in the diagnosis of influenza A. Acta Virol. 20:66–69.

9. Ziegler, T., J. M. Katz, N. J. Cox, and H. L. Regnery. 1997. Influenza viruses, p. 673–678. In N. R. Rose, E. C. de Macario, J. D. Fields, H. C. Lane, and R. M. Nakamura (ed.), Manual of clinical laboratory immunology, 5th ed. American Society for Microbiology, Washington, DC.